Skip to content

NR (Nicotinamide Riboside)

A precursor that raises cellular NAD+, the coenzyme central to mitochondrial energy and sirtuin/DNA-repair pathways, which declines with age.

  • CategoryLongevity & Antioxidants
  • FormNiaCel
  • EvidenceClinical trials on file

Where to get NR (Nicotinamide Riboside)

Thorne
NiaCel 400

10% off is applied automatically through Cam’s partner link, so there is no code to enter.

Shop at Thorne

The short version

  • What it doesNicotinamide riboside exists as a product because of one enzyme that most other NAD precursors do not use. Nicotinamide riboside kinases 1 and 2 phosphorylate it directly to nicotinamide mononucleotide, which nicotinamide mononucleotide adenylyltransferase then converts to NAD+.
  • Who it is forLongevity/energy experimenters, older adults, mitochondrial support.
  • What to watchWell tolerated; nausea, flushing, fatigue and headache in trials, at rates close to placebo.

How NR (Nicotinamide Riboside) works

NAD+ is the coenzyme that accepts electrons throughout energy metabolism and is also consumed as a substrate by the sirtuins and PARPs — the enzymes handling DNA repair and much stress-response signaling. Levels fall with age.

Read the rest of how it works

NR enters cells intact and is phosphorylated by nicotinamide riboside kinase to NMN, then converted to NAD+ — a short, well-mapped route that avoids the flushing of high-dose niacin. That NR raises blood NAD+ in humans is genuinely established; what that increase does downstream is the open question.

NR (Nicotinamide Riboside): serving, timing and spacing

Suggested serving
300–600 mg daily.
How often
Daily
When
Morning with food - NAD+ precursors track the circadian rhythm and evening dosing disturbs sleep in some people

General referenceA general reference intake for education, not a prescription. The label on the product you buy is the final word.

Good to know: Raising NAD+ is proven; the downstream anti-aging benefits are still being tested — set honest expectations.

Research on NR (Nicotinamide Riboside)4 evidence notes: clinical, correlative, theoretical

Each note sits under the kind of evidence it stands on. A thin or missing trial means nobody has run it yet, not that it doesn’t work. How the evidence tiers work

Human clinical evidence

  • RCTs reliably raise blood NAD+ levels in a dose-dependent way (well-established).

  • Human functional-outcome trials (energy, aging markers) are mixed and still emerging.

Correlative data

  • NAD+ declines with age and tracks with metabolic and mitochondrial dysfunction.

Theoretical / extrapolated benefits

  • Anti-aging, DNA-repair and healthspan claims follow from the NAD+/sirtuin mechanism but remain largely unproven as human longevity outcomes.

Sources read for this page

  • Martens CR, Denman BA, Mazzo MR, Armstrong ML, Reisdorph N, McQueen MB, Chonchol M, Seals DR. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults.. Nat Commun 2018 · PMID 29599478
  • Trammell SA, et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nature Communications 2016 · PMID 27721479
  • Brakedal B, et al. The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease. Cell Metabolism 2022 · PMID 35235774
  • Berven H, et al. NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson's disease. Nature Communications 2023 · PMID 38016950
  • Gaare JJ. Nicotinamide riboside supplementation is not associated with altered methylation homeostasis in Parkinson's disease. iScience 2023 · PMID 36936793
  • Harrison DE, et al. 17-a-estradiol late in life extends lifespan in aging UM-HET3 male mice; nicotinamide riboside and three other drugs do not affect lifespan in either sex. Aging Cell 2021 · PMID 33788371

NR (Nicotinamide Riboside), the deep readThe mechanism, cell to human, which form, how you would know

What NR (Nicotinamide Riboside) actually does

Nicotinamide riboside exists as a product because of one enzyme that most other NAD precursors do not use. Nicotinamide riboside kinases 1 and 2 phosphorylate it directly to nicotinamide mononucleotide, which nicotinamide mononucleotide adenylyltransferase then converts to NAD+. That is a two-step salvage route. Nicotinamide, the cheap form, has to go through nicotinamide phosphoribosyltransferase, which is feedback-inhibited by its own product and is the rate-limiting step of the whole salvage pathway Trammell 2016.

What NAD+ is for splits into two jobs with different economics. As a redox cofactor it cycles between NAD+ and NADH without being consumed — glycolysis, the citric acid cycle and oxidative phosphorylation all borrow it and give it back. As a substrate it is destroyed: sirtuins cleave it to transfer an acetyl group, PARP1 consumes it to build poly-ADP-ribose chains during DNA repair, and CD38 hydrolyzes it as an ectoenzyme. Only the second job creates a demand that a supplement could meet.

The decline everyone cites has a named culprit and it is not reduced synthesis. Tissue NAD+ falls with age largely because CD38 expression rises on inflammatory cells and consumes it, and because PARP activation increases with accumulated DNA damage. If consumption is the problem, adding substrate is a way of feeding a leak rather than fixing it — which is a testable difference and the reason CD38 inhibitors are being developed alongside precursors.

Where the precursor goes is not entirely under its own control. A substantial fraction of oral nicotinamide riboside is cleaved to nicotinamide before or during absorption, by the gut microbiota and by purine nucleoside phosphorylase, so part of the dose arrives as the cheap precursor it was meant to improve on Trammell 2016.

And the compartment that matters is not the one that gets measured. Whole blood NAD+ is dominated by erythrocytes, which have a large NAD pool, no mitochondria and no sirtuin-driven consumption. A doubling of blood NAD+ is therefore compatible with very little change in the muscle or brain NAD+ the mechanism is about Martens 2018.

Cell, rodent, human — and where it stops

The biomarker on this page is one of the most reliable in the whole supplement literature, and it has now been followed to three different clinical endpoints without producing one.

The first human study established both the route and the marker. Nicotinamide riboside was shown to be uniquely and orally bioavailable in mice and humans, raising blood NAD+ in a dose-dependent way Trammell 2016. That result is the foundation of the category.

The chronic human trial confirmed it and found nothing else. Six weeks of 1,000 mg a day in healthy middle-aged and older adults was well tolerated and roughly doubled whole blood NAD+ — and did not significantly change most of the physiological outcomes measured alongside it Martens 2018. The surrogate could not have performed better and the endpoints did not follow.

In Parkinson's disease somebody did the harder version of the experiment. The NADPARK study measured NAD+ in the brain by magnetic resonance spectroscopy and in muscle, confirming that oral nicotinamide riboside reaches the tissue that matters Brakedal 2022. A high-dose safety trial then established tolerability at 3,000 mg a day Berven 2023. So the compound gets in, at dose, safely.

And the mechanistic follow-ups keep returning null. Supplementation was not associated with altered methylation homeostasis in the same population Gaare 2023, which tests one of the most-cited theoretical concerns and one of the most-cited proposed benefits at the same time.

The animal endpoint that would have carried the whole field failed under controlled conditions. In the Interventions Testing Program, nicotinamide riboside did not affect lifespan in either sex of genetically heterogeneous mice, in a protocol designed specifically to eliminate the site and husbandry artifacts that inflate lifespan claims Harrison 2021. The obstacle to transfer here is not species and not dose. It is that raising the substrate did not do what the model said it would, in the model.

NR (Nicotinamide Riboside) — which form, and does it matter

The salt on the label decides the stability, and the trials used one of them. Nicotinamide riboside chloride is the material in the human trials. The hydrogen malate salt in this catalog's product is a different counterion chosen for stability; nicotinamide riboside is hygroscopic and degrades to nicotinamide in moist or warm conditions, which is a real shelf problem rather than a theoretical one.

Against nicotinamide mononucleotide, the difference is a phosphate and a transporter argument. Nicotinamide mononucleotide carries a phosphate group, which a cell membrane does not welcome; the prevailing view is that it is dephosphorylated to nicotinamide riboside at the brush border before uptake, which would make the two products converge. A dedicated mononucleotide transporter has been described in mouse gut and its relevance in humans is unresolved.

The pharmacokinetics are fast and the marker is slow. Plasma nicotinamide riboside peaks within about an hour and is cleared within a few hours, while whole blood NAD+ rises over days to weeks and plateaus by around 2 to 4 weeks Martens 2018. First-pass handling is substantial: hepatic and microbial cleavage to nicotinamide means the liver sees a large nicotinamide load whatever the label says. Methylation by nicotinamide N-methyltransferase to N1-methylnicotinamide and then oxidation to the pyridones precedes renal clearance, and those pyridones are the metabolites that turned out to matter on the niacin page.

That methylation step is the reason the trimethylglycine pairings exist. Disposing of a large nicotinamide load consumes S-adenosylmethionine, so combination products add betaine as a methyl donor. Whether that is necessary at supplemental doses has been tested at least once, and methylation homeostasis was not disturbed Gaare 2023.

The practical form question nobody answers on the label. How much of the declared nicotinamide riboside is still nicotinamide riboside at the point of sale. Because degradation gives nicotinamide — a legitimate NAD precursor and a far cheaper one — a degraded product still raises blood NAD+ and still passes a naive assay of the outcome the buyer is checking.

What would have to be true, and how you would know it was not

1. Blood NAD+ will roughly double, and it is the most dependable prediction in this cohort. Predict whole blood NAD+ up substantially within 2 to 4 weeks on 300 to 1,000 mg a day, plateauing thereafter Martens 2018 Trammell 2016. If it does not rise, the product has degraded.

2. Predict the physiological read-outs do not follow. Predict no change in blood pressure, in flow-mediated dilation, in VO2, in grip strength or in body composition at 6 to 12 weeks, because a trial that raised the marker maximally reported essentially that Martens 2018. Choose two of those, measure them, and hold the product to them rather than to the NAD+ number.

3. The prediction that cuts against the product. Predict that no randomized trial will show a clinical benefit that tracks with the size of the NAD+ rise, because the trials that measured brain and muscle NAD+ directly did not find one Brakedal 2022 Gaare 2023. A dose-response trial in which the magnitude of the NAD+ increase predicted the magnitude of a clinical change would falsify this page, and would be the single most valuable study the field could run.

4. Predict a homocysteine drift and watch it if the dose is high. Methyl consumption by nicotinamide N-methyltransferase is a real biochemical cost. Predict homocysteine to be unchanged at 300 mg and worth checking at 1,000 mg or above, and predict that a methylation panel returns to baseline once the dose comes down Gaare 2023.

5. Predict that the lifespan claim stays an animal claim, and note that the animal claim already failed. Predict no human lifespan or healthspan trial will report before the next decade, and note that the best-controlled mouse lifespan protocol returned a null Harrison 2021. An Interventions Testing Program replication showing extension would change this page.

What nobody has tested yet

Nobody knows which tissue NAD+ pool matters. Blood, muscle and brain NAD+ have all been measured in supplemented humans Martens 2018 Brakedal 2022, and no study has established which of them, if any, relates to a clinical outcome. That is the question the whole category rests on and it is open.

The consumption side has never been tested against the supply side. If CD38-driven degradation rather than reduced synthesis causes the age-related decline, a precursor is the wrong intervention. A trial comparing a precursor against a CD38 inhibitor, or the two together, has not been run in people.

Nobody has compared nicotinamide riboside with plain nicotinamide at equal molar dose. Nicotinamide costs a fraction as much and raises NAD+ too. A head-to-head trial with tissue NAD+ as the endpoint would either justify the price of the category or end it Trammell 2016.

And the pyridone question is now unavoidable. Excess nicotinamide is methylated and oxidized to the same terminal metabolites implicated in vascular inflammation in the niacin literature, and no NAD-precursor trial has measured them. Given that high-dose trials exist and are safe by conventional measures Berven 2023, adding that assay to a stored sample set would be cheap and consequential.

NR (Nicotinamide Riboside) — its own safety story, not its category's

Tolerability is genuinely well established, including at doses far above the label. A randomized, double-blind safety trial at 3,000 mg a day found the compound tolerable Berven 2023, and the six-week trial at 1,000 mg reported no safety signal Martens 2018. Nausea, flushing and headache are the usual complaints and are dose-related.

The methyl group budget is the one real biochemical cost. Disposing of a nicotinamide load consumes S-adenosylmethionine, and in principle a chronic high dose could shift methylation elsewhere. The one study that looked found no disturbance of methylation homeostasis, which is reassuring for the doses tested and does not extend to indefinite use Gaare 2023.

The theoretical concern that will not go away is cancer, and it cuts both ways. NAD+ supports PARP-mediated DNA repair, which argues for protection, and it also supports the metabolic demands of proliferating cells, which argues the other way. Preclinical work exists on both sides, no human data address it, and anybody with an active malignancy should treat this as a conversation with an oncologist rather than a supplement decision.

The interaction list is short and specific. There is no cytochrome-mediated interaction of note. The plausible ones are additive: other NAD precursors, high-dose nicotinamide from a B-complex, and nicotinic acid, all of which converge on the same methylation and pyridone disposal route.

Who this is not established for. Pregnancy and lactation, where there are no data. Children, for the same reason. And anyone expecting it to do what the marketing implies: the honest summary is a supplement that reliably does one measurable thing and has not yet been shown to do anything downstream of it. Nothing here is medical advice or diagnosis, and these statements have not been evaluated by the Food and Drug Administration.

NR (Nicotinamide Riboside) safety basics3 points of its own

Its own safety story

  • Well tolerated; nausea, flushing, fatigue and headache in trials, at rates close to placebo.
  • Same unresolved proliferation question as NMN — the mechanism that restores NAD+ is not selective about which cells it restores it in.
  • Better human trial coverage than NMN, and a clearer regulatory position. Long-term safety has not been characterized — the trials run weeks to months, not years. That is a real limit on what anyone can tell you about daily use for a decade.

Not medical advice. If you take prescription medication or have a diagnosed condition, check this against it with a pharmacist or doctor. Pharmacists are underused and free.

Bloodwork to run5 tests in one order, code CAMERON

NR (Nicotinamide Riboside) FAQ5 common questions

What is NR (Nicotinamide Riboside)?
A precursor that raises cellular NAD+, the coenzyme central to mitochondrial energy and sirtuin/DNA-repair pathways, which declines with age.
What is the suggested dose of NR (Nicotinamide Riboside)?
300–600 mg daily. This is a general reference for education only. Statements have not been evaluated by the FDA and this is not medical advice.
Who is NR (Nicotinamide Riboside) for?
Longevity/energy experimenters, older adults, mitochondrial support.
Which labs show whether NR (Nicotinamide Riboside) is doing anything?
hs-CRP (High-Sensitivity C-Reactive Protein), ApoB (Apolipoprotein B), HbA1c (Hemoglobin A1c), Comprehensive Metabolic Panel (CMP), Homocysteine. Draw a baseline before you start, then recheck.
Where can I buy NR (Nicotinamide Riboside)?
Coach Cam sources NR (Nicotinamide Riboside) from Thorne, with 10% off applied automatically at checkout. Use the buy link on this page.
The Before-You-Stack Lab Kit cover

The free Before‑You‑Stack Lab Kit

The 12 labs I’d run before any protocol, what each one tells you, add-ons by goal and how to order them yourself. The PDF is yours straight away.

After that it is about two emails a week: a marker, a compound or a protocol. Unsubscribe in one click.

The full stack plan is inside Skool

This page covers what NR (Nicotinamide Riboside) is, what the research says and how people take it. Skool puts it in order alongside everything else you run, peptides included.

Free on this page

What NR (Nicotinamide Riboside) is and how it works · The serving, its basis, and its safety lines · The research and the bloodwork that shows it

  • What NR (Nicotinamide Riboside) is and how it works
  • The serving, its basis, and its safety lines
  • The research and the bloodwork that shows it

Members get

  • NR (Nicotinamide Riboside) in your full stack: what it runs with, and what it cancels out
  • How it fits with your peptides: what it pairs with, and what it overlaps
  • The retest plan: hs-CRP (High-Sensitivity C-Reactive Protein) baseline, the recheck, what a change means
Join Skool $10/mo1,500+ members, 5.0 rating from 15 reviews. Cancel anytime.
The members' Prep Bench in Skool: the compound finder (no dose shown)
The members’ Prep Bench

Want it built around you?

The coaching app, with sample data

1-on-1 coaching with Cam

Your plan, your bloodwork and your check-ins, built around you.

Research Protocol $150/mo · Full Coaching $250/mo

See coaching

One question? Book a 15-minute consult

A call with Cam on the one thing you are stuck on.

$75 per call

Book a consult

Educational reference only. Not medical advice. These statements have not been evaluated by the FDA and are not intended to diagnose, treat, cure or prevent any disease. Some links are affiliate links; Cam may earn a commission at no extra cost to you. Medical disclaimer & affiliate disclosure

Buy with 10% offJoin Skool